Hemorrhoid Treatment Devices Market Size & Share Analysis - Growth Trends And Forecast (2025 - 2030)

Global Hemorrhoid Treatment Devices Market Trends and Insights

Rising Prevalence of Symptomatic Hemorrhoids

Nearly 10 million Americans were affected by symptomatic hemorrhoids in 2024^{[1]Ashburn, "Jean H., Hemorrhoidal Disease: A Review," Journal of the American Medical Association, ovid.com}, representing about 5% of the adult population. The incidence rate rises sharply after age 50, ensuring a sustained patient pool as the population ages demographically. Sedentary work patterns, high-fat diets, and increasing obesity intensify symptom severity, especially in urban centers where advanced treatment is readily accessible. As emerging economies age and adopt similar lifestyles, epidemiological curves in those regions are expected to track those of developed markets. Together, these factors underpin a broad and predictable demand base that supports continued expansion of the hemorrhoid treatment devices market

Preference for Minimally Invasive Outpatient Procedures

Patients and payers alike prefer procedures that shorten recovery and avoid overnight admission. Medicare reimburses key hemorrhoid ligation codes, making outpatient treatment financially attractive for providers. Laser hemorrhoidoplasty patients in a 2024 case series reported no pain or bleeding by day 4^{[2]Fadli Robby Amsriza, "Laser Hemorrhoidoplasty Using Reusable Bare Fiber Combined Mucopexy on Grade IV Internal Hemorrhoid: A Case Report," Jurnal Ilmiah Kedokteran Wijaya Kusuma, researchgate.net}, highlighting a faster convalescence compared to open surgery. Ambulatory surgical centers, which combine specialized staff with high-throughput workflows, are capturing a growing share of the volume. Collectively, these trends accelerate migration away from inpatient settings and reinforce steady demand for advanced devices.

Technological Advances

The integration of real-time imaging, embedded sensors, and artificial intelligence enhances precision and reduces complication risk. THD Revolution combines high-sensitivity Doppler technology with ergonomic LED illumination, enabling surgeons to identify feeder vessels and reduce recurrence rates quickly. AI-powered colonoscopy systems such as CADDIE improve adenoma detection to 58.7%, up from 46.3%^{[3]Rawen Kader, "O51 Randomised controlled trial of a cloud-based artificial intelligence polyp detection system (CADDIE)," Gut, gut.bmj.com} under standard HD visualization. The convergence of diagnostics and therapeutics on a single platform shortens procedure time, simplifies training, and widens physician adoption, thereby propelling the hemorrhoid treatment devices market forward.

Healthcare Expenditure Growth in Asia-Pacific

Governments across the Asia-Pacific region continue to expand insurance coverage and expedite device approvals. China’s 2024 medical device law reduced the average review time and improved transparency, facilitating easier foreign market entry. India’s new marketing conduct codes promote ethical promotion, giving established manufacturers with robust compliance frameworks a competitive edge. As disposable incomes rise, older adults in the region are more willing to seek interventional care rather than rely on topical remedies. These dynamics create a long-term boost in regional demand and position the Asia-Pacific region as the fastest-growing area of the hemorrhoid treatment devices market.

Limited Reimbursement in Developing Markets

In many emerging economies, insurance budgets prioritize communicable diseases and maternal health, so hemorrhoid interventions are often paid out-of-pocket. The high ticket price of Doppler-guided or laser systems places them out of reach for lower-income patients, leading to a two-tiered market where affluent urban citizens access advanced care while rural populations rely on conservative management. This gap dampens overall installed-base growth, slows training uptake among clinicians, and tempers the long-run CAGR of the hemorrhoid treatment devices market.

OTC Topical Products Delaying Device Adoption

Widely advertised creams and suppositories promise instant relief at a fraction of procedural cost, so many sufferers self-medicate for months before consulting a physician. Repeated topical use can mask progression to grade III or IV disease that ultimately requires more complex intervention^{[4]Stephen W. Leslie, "Vesicoureteral Reflux," StatPearls Publishing, ncbi.nlm.nih.gov}, raising clinical burden and cost. Because these OTC options are profitable for pharmacies and convenient for patients, device manufacturers must invest in patient education to accelerate the path from symptom onset to definitive care. Until that awareness gap narrows, the hemorrhoid treatment devices industry will face a modest headwind in procedure volumes.

Segment Analysis

By Product Type: Precision Drives Uptake of Doppler Systems

Rubber band ligators remained the leader, accounting for 42.32% of the 2024 hemorrhoid treatment devices market share, reflecting decades of clinical familiarity, low unit costs, and minimal capital requirements. Doppler-guided ligation systems, however, are on a faster growth trajectory, posting a 6.46% CAGR to 2030 as surgeons migrate to real-time vessel localization, which curbs recurrence. The THD Revolution platform exemplifies this shift with integrated imaging, intuitive controls, and sterility-optimized accessories. Infrared coagulators and sclerotherapy injectors maintain relevance for grades I and II disease, where tissue sparing is paramount. Bipolar probes supply targeted thermal energy for select patient groups, whereas cryotherapy devices find niche application in districts where disposables remain cost-prohibitive. As sustainability regulations tighten, producers are exploring biopolymer housings and single-use kits that strike a balance between infection control and environmental impact. Such design innovations are expected to preserve the value proposition of entry-level ligators while nudging the category into higher-margin territory.

Note: Segment shares of all individual segments available upon report purchase

By Procedure Setting: Endoscopic Platforms Extend Leadership

Endoscopic ligations, combined with diagnostic visualization, captured 58.01% of the 2024 revenue. Cap-assisted, AI-supported techniques offer painless band placement, quick turnover, and nearly 90% symptom resolution, so they are gaining preference among gastroenterologists. The hemorrhoid treatment devices market size for endoscopic platforms is expected to grow at a 6.01% CAGR, driven by software upgrades such as Medtronic’s ColonPRO, which enhance polyp recognition and reduce false positives by 9%. Non-endoscopic outpatient approaches still appeal to resource-constrained clinics; rubber band ligation or sclerosant injections remain quick and affordable when high-definition towers are unavailable. Yet ongoing physician-training initiatives and falling capital costs should continue to tilt volumes toward endoscopic modalities. The direct link between early detection, same-session therapy, and durable symptom relief keeps this setting at the forefront of the hemorrhoid treatment devices market.

By End User: Ambulatory Centers Earn a Growth Premium

Hospitals retained a 53.82% revenue share in 2024, leveraging multidisciplinary teams and broad anesthesia capabilities to handle complex cases. Ambulatory surgical centers, however, captured the growth premium with a 6.41% projected CAGR, aided by bundled-payment incentives, predictable scheduling, and patient preference for same-day discharge. Specialty clinics sit between the two extremes, offering targeted expertise without the overhead of tertiary hospitals, and they are adopting office-based systems, such as HemWell, that shorten procedure times for grade II-III disease. Manufacturers are tailoring products to each channel: modular towers for hospitals, compact single-use kits for ASCs, and portable ligators for clinics. This segmentation supports parallel growth paths and reinforces resilience across the hemorrhoid treatment devices market.

Geography Analysis

North America held the leading 42.23% revenue share in 2024, supported by Medicare coverage for CPT codes 46221, 46945, and 46946, which pay providers an average of USD 400 per procedure. Strong hospital infrastructure, widespread availability of high-definition endoscopes, and expedited FDA pathways for Class II ligators underpin the region’s dominance.

The Asia-Pacific region is the fastest-growing geography, with a 6.35% CAGR forecasted to 2030. China streamlined its device registration framework in 2024, reducing average review cycles and enhancing post-market surveillance, which in turn boosts both foreign and domestic investment. India’s marketing conduct code formalized promotional standards, rewarding multinational producers that maintain rigorous compliance. Olympus recorded 32% year-over-year gains in North America, while reporting strong therapeutic endoscopy demand in Asia, confirming the cross-regional transferability of GI platforms. Urbanizing populations, rising disposable income, and heightened health awareness combine to create sustained momentum for advanced hemorrhoid interventions.

Europe represents a mature yet resilient market. Strict infection-control mandates and environmental directives encourage single-use device adoption, pushing manufacturers to redesign ligators with recyclable bio-polymers. Reimbursement structures vary, yet most national payers now cover Doppler-guided procedures for higher-grade disease, underpinning steady replacement cycles. South America and the Middle East & Africa remain emerging segments: limited reimbursement and fewer trained proctologists cap uptake outside major cities, although rising employer-sponsored insurance and public-sector infrastructure projects are gradually widening access to device-based care.